Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Simcerely Yours: Simcere Buys Majority Stake In Fellow Chinese Pharma Boda

This article was originally published in PharmAsia News

Executive Summary

Continuing its acquisition strategy, Simcere Pharmaceutical Group, one of China's largest branded generics manufacturers, bought a 51 percent stake in Boda Pharmaceutical in a deal valued at $14.8 million (RMB 111 million), Simcere announced Sept. 28

You may also be interested in...



Simcere Reports Increased Growth In First Quarter Results, Eyes Future M&As

Chinese Simcere Reports Fourth Quarter Sales Growth; Preparing For Health Care Reforms

SHANGHAI - China-based Simcere Pharmaceutical Group reported a spike in the sales of its two main products, anti-cancer drug Endu and injectable edaravone Bicun in its fourth quarter 2007 financial results.

Chinese Simcere Reports Fourth Quarter Sales Growth; Preparing For Health Care Reforms

SHANGHAI - China-based Simcere Pharmaceutical Group reported a spike in the sales of its two main products, anti-cancer drug Endu and injectable edaravone Bicun in its fourth quarter 2007 financial results.

UsernamePublicRestriction

Register

LL1134885

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel